LATAM OTC Results Round-Up: Mexico's Genomma Lab, Brazil's Hypera

Genomma enjoys broad-based growth in 2018, while NPD investments pay off for Hypera.

Coins
• Source: Shutterstock

Mexico’s Genomma Lab Internacional SAB de CVreported OTC sales up by 14.2% to MXN6.07bn ($314m) in 2018, as turnover improved at a double-digit rate in all three of its reporting regions.

The 14.2% growth rate had been thanks to “key trade initiatives implemented across the regions during 2018 to enhance point of sale execution and visibility,” the firm noted.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Galenica’s Verfora Gets Off To Flying Start In Swiss CHC Market

 
• By 

Verfora grows almost 10-times faster than the Swiss consumer health market in the opening months of 2025.

IQVIA Consumer Health: Digestive Category Driving Global OTC Market Growth

 
• By 

An increasing awareness of and interest in gut health helped the global OTC market grow by 4.6% in value terms in 2024, according to IQVIA Consumer Health.

Recordati Relying On OTC To Act As ‘Booster’ To Growth

 
• By 

In categories like cough & cold and gastrointestinal, OTC products have a pivotal role to play in helping Recordati hit its sales targets for the 2025-2027 period.

Bayer Consumer Health Delivers ‘Balanced’ Q1

 
• By 

With sales gains across most of its regions and product categories, Bayer Consumer Health got off to a good start to the year.

More from Business

People On The Move: Appointments At ANEPF, Inula, Opella

 
• By 

A round-up of the latest consumer health people moves: ANEFP elects president; Inula Group appoints CEO; Opella names ANZ head.

Over The Counter: Taking Real-World Evidence Seriously, With IQVIA Consumer Health’s Volker Spitzer

 
• By 

In part 2 of HBW Insight's interview, IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer, explains how to approach real world evidence so that regulators recognize its validity, in supporting Rx-to-OTC switch applications, for example.

Recordati Relying On OTC To Act As ‘Booster’ To Growth

 
• By 

In categories like cough & cold and gastrointestinal, OTC products have a pivotal role to play in helping Recordati hit its sales targets for the 2025-2027 period.